DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLIPIZIDE

« Back to Dashboard

Clinical Trials for Glipizide

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00094770	An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)	Completed	Merck Sharp & Dohme Corp.	Phase 3	The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
NCT00116831	Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes	Completed	GlaxoSmithKline	Phase 3	The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
NCT00509236	Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)	Completed	Merck Sharp & Dohme Corp.	Phase 3	The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
NCT00509262	Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)	Completed	Merck Sharp & Dohme Corp.	Phase 3	The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
NCT00513630	Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease	Completed	Shanghai Jiao Tong University School of Medicine	Phase 4	The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation

Clinical Trial Conditions for Glipizide

Condition Name

Condition Name for Glipizide
Intervention	Trials
Type 2 Diabetes	7
Diabetes Mellitus, Type 2	7
Type 2 Diabetes Mellitus	4
Healthy	4

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Glipizide
Intervention	Trials
Diabetes Mellitus	20
Diabetes Mellitus, Type 2	17
Renal Insufficiency, Chronic	3
Kidney Diseases	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Glipizide

Trials by Country

Trials by Country for Glipizide
Location	Trials
United States	89
India	18
Mexico	13
Italy	12
Germany	12

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Glipizide
Location	Trials
North Dakota	6
Illinois	5
California	4
Pennsylvania	4
Texas	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Glipizide

Clinical Trial Phase

Clinical Trial Phase for Glipizide
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	9
Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Glipizide
Clinical Trial Phase	Trials
Completed	24
Unknown status	3
Recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Glipizide

Sponsor Name

Sponsor Name for Glipizide
Sponsor	Trials
Merck Sharp & Dohme Corp.	6
Canadian Network for Observational Drug Effect Studies, CNODES	3
Drug Safety and Effectiveness Network, Canada	3

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Glipizide
Sponsor	Trials
Other	26
Industry	22

Export unavailable in trial.
Subscribe for complete access.